MyFinsight
Home
Blog
About
Comprehensive loss
-$112,181,000
(-33.94%↓ Y/Y)
Net loss
-$110,736,000
(-30.73%↓ Y/Y)
Unrealized gain (loss) on
available-for-sale securities...
-$1,445,000
(-252.27%↓ Y/Y)
Income tax recovery
-$585,000
(6.55%↑ Y/Y)
Interest income
$12,145,000
(68.70%↑ Y/Y)
Loss before income
taxes
-$111,321,000
(-30.46%↓ Y/Y)
Total other income
$11,834,000
(33.01%↑ Y/Y)
Foreign exchange loss
(gain)
-$311,000
(-118.32%↓ Y/Y)
Loss from operations
-$123,155,000
(-30.70%↓ Y/Y)
Total operating
expenses
$123,155,000
(30.70%↑ Y/Y)
Research and development
$99,224,000
(32.33%↑ Y/Y)
General and
administrative
$23,931,000
(24.36%↑ Y/Y)
Back
Back
Income Statement
logo_icon_teal_2280px-svg
Xenon Pharmaceuticals Inc. (XENE)
logo_icon_teal_2280px-svg
source: myfinsight.com
Xenon Pharmaceuticals Inc. (XENE)